Patent SG-11201906530T-A (SG)
Title: Inhibition of platelet aggregation using anti-human gpvi antibodies
Inventor: BILLIALD PHILIPPE
IPC: A61K39/395
Filed: 2018-02-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT ill 1111u°11101VIIIVIIIVIIIoI0 VIIIVIIIVIII I10111110 DIIIIII DID (10) International Publication Number WO 2018/141909 Al (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, C07K 16/28 (2006.01) A61K 39/00 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 39/395 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/EP2018/052664 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (22) International Filing Date: 02 February 2018 (02.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17154658.3 03 February 2017 (03.02.2017) EP (71) Applicants: ACTICOR BIOTECH [FR/FR]; Batiment INSERM U698 HP BICHAT - Secteur Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18 (FR). UNIVERSITE PARIS DIDEROT - PARIS 7 [FR/FR]; 5 me Thomas Mann, 75205 Paris Cedex 13 (FR). UNIVERSITE PARIS XIII [FR/FR]; 99 avenue Jean Baptiste Clement, 93430 Villetaneuse (FR). INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) [FR/FR]; 101 rue de Tol- biac, 75654 Paris Cedex 13 (FR). UNIVERSITE PARIS- SUD 11 [FR/FR]; 15 me Georges Clemenceau, 91400 Or- say (FR). (72) Inventors: BILLIALD, Philippe; 28 me des Sablons, 75116 Paris (FR). JANDROT-PERRUS, Martine; 5 rue Barbes, 92170 Vanves (FR). AVENARD, Gilles; 85 rue Perier, 92120 Montrouge (FR). (74) Agent: ICOSA; 83 avenue Denfert-Rochereau, 75014 Paris (FR). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every 1-1 kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, O TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 71' 1-1 Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) GO (54) Title: INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES 0 (57) : The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI ) for treating \" a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 0 hours to the subject, preferably during at least 4 to 6 hours.